|22.60||+0.3200||+1.44%||Vol 1.18M||1Y Perf 45.24%|
|Dec 1st, 2023 16:00 DELAYED|
|- -||-0.12 -0.53%|
|Target Price||18.47||Analyst Rating||Moderate Buy 2.00|
|Potential %||-18.27||Finscreener Ranking||★★★ 48.90|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★+ 49.24|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★+ 49.46|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||41.71||Earnings Rating||Strong Buy|
|Market Cap||3.71B||Earnings Date||2nd Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.43|
|EPS Growth Next 5 Years %||43.40|
|Avg. Weekly Volume||882.93K|
|Avg. Monthly Volume||1.26M|
|Avg. Quarterly Volume||1.51M|
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stock closed at 22.28 per share at the end of the most recent trading day (a 0.68% change compared to the prior day closing price) with a volume of 1.34M shares and market capitalization of 3.71B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 580 people. ACADIA Pharmaceuticals Inc. CEO is Stephen R. Davis.
The one-year performance of ACADIA Pharmaceuticals Inc. stock is 45.24%, while year-to-date (YTD) performance is 39.95%. ACAD stock has a five-year performance of 16.89%. Its 52-week range is between 14.45 and 33.99, which gives ACAD stock a 52-week price range ratio of 41.71%
ACADIA Pharmaceuticals Inc. currently has a PE ratio of -12.80, a price-to-book (PB) ratio of 6.58, a price-to-sale (PS) ratio of 7.17, a price to cashflow ratio of -, a PEG ratio of -0.29, a ROA of -29.57%, a ROC of -39.09% and a ROE of -39.13%. The company’s profit margin is -45.77%, its EBITDA margin is -43.00%, and its revenue ttm is $380.74 Million , which makes it $2.35 revenue per share.
Of the last four earnings reports from ACADIA Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.43 for the next earnings report. ACADIA Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for ACADIA Pharmaceuticals Inc. is Moderate Buy (2), with a target price of $18.47, which is -18.27% compared to the current price. The earnings rating for ACADIA Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ACADIA Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ACADIA Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.16, ATR14 : 0.77, CCI20 : -52.46, Chaikin Money Flow : 0.09, MACD : -0.23, Money Flow Index : 52.78, ROC : 0.36, RSI : 46.48, STOCH (14,3) : 38.67, STOCH RSI : 0.99, UO : 52.00, Williams %R : -61.33), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ACADIA Pharmaceuticals Inc. in the last 12-months were: Austin D. Kim (Option Excercise at a value of $0), Austin D. Kim (Sold 1 392 shares of value $25 170 ), Baker Julian (Option Excercise at a value of $78 300), Brendan P. Teehan (Option Excercise at a value of $0), Brendan P. Teehan (Sold 993 shares of value $17 771 ), Daniel Soland (Option Excercise at a value of $0), Davis Stephen (Option Excercise at a value of $0), Davis Stephen (Sold 75 706 shares of value $1 592 701 ), Edmund P. Harrigan (Option Excercise at a value of $0), Garofalo Elizabeth (Option Excercise at a value of $0), James Daly (Option Excercise at a value of $0), James K. Kihara (Option Excercise at a value of $0), James K. Kihara (Sold 350 shares of value $6 573 ), James Kihara (Sold 0 shares of value $0 ), James Kihara (Sold 13 506 shares of value $307 598 ), Kim Austin (Option Excercise at a value of $0), Kim Austin (Sold 20 134 shares of value $430 496 ), Laura A. Brege (Option Excercise at a value of $212 625), Laura A. Brege (Sold 12 500 shares of value $228 125 ), Laura Brege (Option Excercise at a value of $212 625), Laura Brege (Sold 4 500 shares of value $111 915 ), Mark C. Schneyer (Option Excercise at a value of $0), Mark C. Schneyer (Sold 577 shares of value $10 836 ), Ndu Adora (Sold 0 shares of value $0 ), Schneyer Mark (Sold 0 shares of value $0 ), Schneyer Mark (Sold 33 885 shares of value $820 120 ), Schneyer Mark C. (Option Exercise at a value of $0), Schneyer Mark C. (Sold 974 shares of value $24 369 ), Stephen R. Davis (Option Excercise at a value of $0), Stephen R. Davis (Sold 7 755 shares of value $139 198 ), Teehan Brendan (Option Excercise at a value of $0), Teehan Brendan (Sold 23 121 shares of value $508 022 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.